Is Abbvie Stock Underperforming the S&P 500?

North Chicago-based Abbvie Incorporated (ABBV) stands as a titan in the global biotechnology landscape, boasting a market cap of $282.9 billion. The company's formidable portfolio is anchored by a suite of groundbreaking drugs, including blockbuster treatments such as Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta. Abbvie's unparalleled expertise and leadership in various therapeutic areas, from neuroscience and aesthetics to eye care and women's health, cements its position as a prominent industry player, setting it apart from competitors like Amgen Incorporated (AMGN). 

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and Abbvie fits right into that category. Its market cap exceeds this threshold, reflecting its substantial size, stability, and influence in the pharmaceutical sector. The pharma giant has achieved a leading position in the market, particularly in the areas of immunology and oncology, through its strong portfolio of products.